Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer

<div>Prognostic analysis of OV samples between high- and low-score groups. (a) The distributions of response and nonresponse samples between high- and low-score groups. (b, c) The overall survival rate and progression-free survival rate of high- and low-score group samples in TCGA-OV dataset. The cross symbols indicated censored samples. The 95% confidence intervals were also presented in (b) and (c).</div>

Journal of Immunology Research

fig4

Figure 4

Figure 4: Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer 

Figure 4 | Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer 